About Bioline  All Journals  Testimonials  Membership  News

Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
ISSN: 1596-5996
EISSN: 1596-5996
Vol. 13, No. 4, 2014, pp. 527-532
Bioline Code: pr14075
Full paper language: English
Document type: Research Article
Document available free of charge

Tropical Journal of Pharmaceutical Research, Vol. 13, No. 4, 2014, pp. 527-532

 en Evaluation of Genotoxicity of CSE1034 by Ames and In vitro Chromosomal Aberration Tests
Chaudhary, Manu & Payasi, Anurag


Purpose: To evaluate the genotoxicity of CSE1034, a novel antibiotic adjuvant entity, using bacterial reverse mutation assay (Ames test) and in vitro chromosomal aberration test.
Methods: Reverse mutation test was carried out using four strains of Salmonella typhimurium (TA 98, TA100, TA1535 and TA1537) and one strain of E. coli [WP2 (uvrA)], while chromosomal aberration test was done with cultured Chinese hamster lung (CHL) cells. Reverse mutation test was carried out in a dose range of 0.0015 to 0.16 μg/plate in triplicate with and without S9 activation.
Results: No significant increases in the number of revertants were observed at the dose levels where antibacterial effects were not noted. CSE1034 caused no increase in the number of chromosomal aberrants at dose levels of 0.34, 0.69, 1.37, 2.75 and 5.50 mg/ml in the absence and presence of metabolic activation.
Conclusion: Based on the above observations, it can be concluded that CSE1034 has no mutagenic activity.

CSE1034; reverse mutation; antibiotic adjuvant entity; Chromosomal aberration; Mutagenic

© Copyright 2014 - Tropical Journal of Pharmaceutical Research
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil